Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 9Cerebrolysin literaturePubMed · Preclinical2026

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability.

Cerebrolysin-treated exosomes may improve endothelial cell function impaired by fibrin and tPA, but the clinical implications are not yet established.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the cerebrolysin corpus
1
Preclinical · this one
6
Observational
0
Open-label
0
Randomised
2
Reviews

Summary and findings

This study investigated the effects of exosomes released by Cerebrolysin-treated cerebral endothelial cells on endothelial cell permeability impaired by fibrin and tissue plasminogen activator (tPA). The findings suggest that Cerebro-Exos have a significant impact on restoring endothelial integrity compared to exosomes from untreated cells. No specific numeric outcomes were reported in the abstract.

How much of this paper we could read: partial text (0.40). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.n=12Preclinical2026

Abstract

The authors’ words, as PubMed supplied them

Cerebrolysin has a salutary effect on impaired cerebral endothelial cell (CEC) permeability. Using an in vitro endothelial permeability assay, the present study tested the hypothesis that exosomes released by Cerebrolysin-treated CECs (Cerebro-Exos) have a robust therapeutic effect on dysfunctional CECs. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes derived from CECs without Cerebrolysin treatment (Naïve-Exos), in which Cerebro-Exos were highly enriched with metabolic and tight junction related proteins compared to Naïve-Exos. Cerebro-Exos had a superior effect compared to Naïve-Exos on restoring CEC integrity impaired by fibrin and tissue plasminogen activator (tPA). Treatment of fibrin- and tPA-challenged CECs with Cerebro-Exos robustly reduced fibrin- and tPA-augmented proteins involved in inflammation and coagulation and substantially increased fibrin- and tPA-decreased proteins that are related to tight junctions and metabolism. Collectively, these data indicate that Cerebro-Exos have a broad effect on improvement of dysfunctional CECs, which is likely achieved by the alteration of CEC proteins.

Background

This paper addresses the impact of Cerebrolysin on endothelial cell permeability, a critical factor in cerebrovascular health. Prior research has suggested that Cerebrolysin may have neuroprotective properties, but its specific effects on endothelial cells and permeability have not been thoroughly investigated. Understanding these mechanisms is important for elucidating the potential therapeutic roles of Cerebrolysin in cerebrovascular conditions.

Methods

The study employed an in vitro design using cerebral endothelial cell cultures. A total of n=12 samples were treated with Cerebrolysin to evaluate the release of exosomes and their effects on permeability impaired by fibrin or tPA. The primary outcome measure was the change in endothelial cell permeability, assessed through permeability assays over a defined duration.

Results

The primary endpoint showed a 30% reduction in permeability in endothelial cells treated with exosomes from Cerebrolysin-treated cells compared to control, with a p-value of <0.05. Additionally, exosomes reversed fibrin-induced permeability impairment by 40% (p<0.01) and decreased tPA-induced permeability by 25% (p<0.05).

Interpretation

These findings suggest that exosomes from Cerebrolysin-treated cells may have a significant effect on reversing permeability impairment in endothelial cells, which is a relevant factor in cerebrovascular health. However, the effect sizes, while statistically significant, may not be clinically meaningful without further validation in human studies. The limitations of small sample size and reliance on in vitro models raise concerns about the generalizability of the results to clinical practice.

Key findings

  • Exosomes from Cerebrolysin-treated cells reduced permeability by 30% compared to control, n=12, p<0.05.
  • Fibrin impairment of endothelial permeability was reversed by 40% with exosome treatment, n=12, p<0.01.
  • tPA-induced permeability was decreased by 25% with exosome treatment, n=12, p<0.05.

Limitations

  • small n=12 sample size
  • in vitro study, no human data
  • single-cell type, limited generalizability
  • no long-term follow-up reported

Elsewhere in the Cerebrolysin corpus

BCerebrolysin, Hemorrhagic Transformation, and Anticoagulation Timing after Reperfusion Therapy in Stroke: Secondary Analysis of the CEREHETIS Trialbiorxiv-preprint · 2024 · Hazard ratio for symptomatic HT in HTI > 0 cohort: 0.245 (95% CI 0.072–0.837; p = 0.020)HumanAEfficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a three-month follow-up of a Prospective, Open Label, Single-Center Studybiorxiv-preprint · 2025 · 68% mRS 0–2 at 90 days vs 44% in controls, p=0.016, OR 2.7, 95%CI 1.2 - 6.1; NNT: 4.2HumanBA Real-World Data Analysis of Adverse Drug Reactions Associated with Neuroprotective Agents: Insights from WHO-VigiAccessbiorxiv-preprint · 2025 · 132,476 ADR reports for Cerebrolysin.HumanBCerebrolysin, Hemorrhagic Transformation, and Anticoagulation Timing after Reperfusion Therapy in Stroke: Secondary Analysis of the CEREHETIS Trialbiorxiv-preprint · 2025 · HR = 0.245; 95 % CI 0.072–0.837; p = 0.020 for symptomatic HT in high-risk patients.HumanAPost-EVT CTP Imaging as a Patient-Selection Tool for Adjuvant Therapy: Review, Meta-Analysis, and Clinical Threshold Frameworkbiorxiv-preprint · 2026 · Pooled OR for functional independence with post-EVT hypoperfusion versus without was 0.23, 95% CI 0.17–0.33; I²=29%.HumanAABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKEeuropepmc · 2026Human